

## Introduction


The renal ciliopathies represent a group of rare inherited kidney diseases affecting around 10% of all patients with kidney failure.

Recently the first drugs have come to the clinic to slow down this disease but treatments that prevent or switch off the disease are still lacking.

<b>AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)</b> 1 : 800 - 2,500 people
<b>AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD)</b> 1 : 20,000 people
<b>SYNDROMIC CYSTIC KIDNEY DISEASE (i.e. BBS)</b> 1 : 125,000 - 170,000 people
<b>SYNDROMIC CYSTIC KIDNEY DISEASE (i.e. NPHP)</b> 1 : 50,000 - 1,000,000 people

Each a rare disease, collectively represent a significant unmet challenge of our healthcare system


## RaDaR Cystic Kidney Disease Data




Cumulative incidence of Kidney Failure

## CILIAREN VISION

- To develop a national network and framework to improve the identification, diagnosis and management of patients with renal ciliopathies
- Educate and train medical practitioners and scientists
- Create a national framework for the identification, investigation and treatment of renal ciliopathies



## Patient, Public Involvement, Engagement and Partners



@CILIAREN

<https://www.ciliaren.org/>

